Last updated: February 13, 2026
Product Overview:
NDC 00093-9477 refers to a specific drug product registered with the FDA. Based on available public data, the product is identified as Eliquis (apixaban), an oral anticoagulant used in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed for the treatment and reduction of risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Market Size and Dynamics
Market Overview
The global anticoagulant market is significant and growing, driven by increasing prevalence of atrial fibrillation, venous thromboembolism, and cardiovascular diseases. The U.S. market for direct oral anticoagulants (DOACs) like Eliquis is mature but continues to expand due to adoption over traditional therapies.
Market Drivers
- Rising aging population
- Increased awareness of stroke prevention strategies
- Expanded indications for anticoagulants
- Favorable reimbursement policies for Eliquis in key territories
Market Challenges
- Competition from other DOACs: Pradaxa (dabigatran), Xarelto (rivaroxaban), and Savaysa (edoxaban)
- Cost considerations impacting prescriber prescribing patterns
- Safety concerns such as bleeding risks
Market Data
In 2022, the U.S. market for Eliquis generated approximately $7.8 billion in revenues, with growth rates averaging 10% annually over the past five years. Globally, the drug's revenues exceeded $10 billion, accounting for about 25% of the total DOAC market [1].
Pricing Trends and Projections
Current Price Point
- Average wholesale price (AWP): ~$4.50 per tablet (30 mg), with variations based on pharmacies and insurance coverage
- Government/Payer Price: Higher discounts apply under Medicaid, Medicare, and commercial insurance formularies
Pricing Factors
- Patent exclusivity restrictions
- Competition from generics (expected post-2026)
- Negotiations and discounts in managed care settings
Anticipated Price Trends
- Short-term stabilization driven by market share dominance
- Long-term decrease in prices with patent expiry (expected around 2026) due to generic entry
- Price erosion estimates: 20-30% over 3-5 years post-generic entry
| Future Price Projections |
Year |
Estimated Retail Price (per tablet) |
Notes |
| 2023 |
~$4.50 |
Current market price |
| 2024 |
~$4.45 |
Slight decrease due to market pressures |
| 2025 |
~$4.20 |
Ongoing pricing stabilization |
| 2026+ |
~$2.50-$3.50 |
Post-patent expiry, generic entry expected |
Market Penetration and Competition
By 2025, Eliquis is projected to maintain a dominant 60-70% share of the DOAC market in the U.S. The arrival of generics will significantly impact pricing and market share distribution. The entry of biosimilars and newer anticoagulants could further influence market dynamics.
Legal and Regulatory Considerations
The patent for Eliquis is set to expire around 2026 in the U.S., after which generic competitors will enter the market. Patent challenges could modify this timeline but are unlikely until that period.
Key Takeaways
- The current U.S. revenue for Eliquis was approximately $7.8 billion in 2022.
- The drug commands an average wholesale price of roughly $4.50 per tablet.
- Price trajectories indicate stabilization until patent expiration around 2026, when a decline to $2.50-$3.50 per tablet is expected.
- Market growth is driven by aging populations and rising cardiovascular disease prevalence.
- The competitive landscape includes Xarelto, Pradaxa, and upcoming generics, which will drive prices downward.
FAQs
1. When is patent expiration for NDC 00093-9477?
The patent is expected to expire around 2026, paving the way for generic competition.
2. How will generic entry affect the price?
Prices are projected to decline 20-30% within 1-2 years after generics become available.
3. What are the main competitors?
Xarelto (rivaroxaban), Pradaxa (dabigatran), and edoxaban are primary competitors with similar indications.
4. How does pricing differ across markets?
Prices are higher at the wholesale level; rebates, discounts, and insurance negotiations impact actual patient costs.
5. What is the potential for biosimilar or new entrants?
Biosimilar development is less relevant for Eliquis as it is a small molecule; new entrants depend on regulatory approvals and market conditions post-2026.
References
- IQVIA. "U.S. Prescription Drug Market Estimates 2022," IQVIA Institute.
